aTyr Pharma presents clinical development program for efzofitimod in pulmonary sarcoidosis.

aTyr Pharma released an investor presentation outlining advancement of efzofitimod, its tRNA synthetase-derived therapeutic candidate, for pulmonary sarcoidosis and additional indications. The filing demonstrates the company's ongoing clinical development efforts and potential market opportunity in immunological diseases.